Clinical Trial: Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension

Brief Summary: Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH. Reduction of left ventricular mass (LVM) with antihypertensive agents is associated with improved clinical outcome. This study will evaluate the effects of amlodipine/benazepril in reducing LVM in patients with high risk hypertension.

Detailed Summary:
Sponsor: Novartis

Current Primary Outcome: Change from baseline in left ventricular mass index after 52 weeks

Original Primary Outcome:

Current Secondary Outcome:

  • Change from baseline in left ventricular mass after 52 weeks
  • Change from baseline in diastolic function after 52 weeks
  • Change from baseline in aorta function assessed blood pressure measurements after 52 weeks
  • Change from baseline in markers of fibrosis and increased heart size after 52 weeks


Original Secondary Outcome:

Information By: Novartis

Dates:
Date Received: August 29, 2005
Date Started: July 2004
Date Completion:
Last Updated: February 21, 2017
Last Verified: February 2017